Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 3/20 | 0.39 |
| ▸ | FEN1 | P39748 | 3/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 10/20 | 0.38 |
| ▸ | INSR | P06213 | 7/20 | 0.37 |
| ▸ | JAK2 | O60674 | 9/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | NPM1 | P06748 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2533530 | 0.90 | ALK (0.38) | ALKINSRJAK2CYP3A4NPM1 | |
| SCHEMBL2536859 | 0.81 | JAK2 (0.40) | ALKINSRJAK2 | |
| SCHEMBL522476 | 0.80 | ALOX5AP (0.42) | ALOX5APFEN1ALKINSRJAK2 | |
| SCHEMBL521875 | 0.78 | ALOX5AP (0.41) | ALOX5APFEN1ALKINSRJAK2 | |
| SCHEMBL2536858 | 0.73 | JAK2 (0.40) | ALKINSRJAK2 | |
| SCHEMBL520303 | 0.70 | JAK2 (0.44) | ALKINSRJAK2CYP3A4 | |
| SCHEMBL522477 | 0.68 | ALK (0.34) | ALKINSRJAK2CYP3A4NPM1 | |
| SCHEMBL521876 | 0.67 | JAK2 (0.33) | ALKINSRJAK2CYP3A4NPM1 | |
| SCHEMBL2530064 | 0.66 | DYRK3 (0.41) | ALKINSRJAK2 | |
| SCHEMBL521498 | 0.62 | JAK2 (0.55) | ALKINSRJAK2CYP3A4NPM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |